Have the HYPERION and ZENITH trial data changed how you sequence sotatercept in a newly diagnosed patient with intermediate-to-high-risk WHO Group 1 PAH — specifically, do you now add sotatercept at diagnosis alongside background dual therapy rather than waiting for inadequate response?
Community PollStarted
In light of HYPERION and ZENITH trial data, do you now add sotatercept at diagnosis alongside background dual therapy rather than waiting for inadequate response?
32 physicians have voted
Join Mednetto vote and see how they answered.